Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Arie Belldegrun


Mr. Arie Belldegrun is a Co-Founder and serves as Senior Managing Director at Vida Ventures (Boston). He serves as Chairman and Partner at Two River Group. A visionary entrepreneur, Arie is co-founding and leading the creation of Allogene Therapeutics, a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Arie founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. He remains as Vice Chairman of the Board of Directors for FosunKite, a joint venture formed between Fosun Pharma and Kite, a Gilead company, for the development of cell therapy in China. Arie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as Chairman of Two River Group and UroGen Pharma, (NASDAQ: URGN), and previously served as a Board Member of Cell Design Labs until its acquisition by Gilead in December 2017. Arie is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He is currently a member of the Parker Institute for Cancer Immunotherapy Strategic Advisory Group. Prior to joining UCLA, Arie was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at Harvard Medical School. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Primary Office
  • Los Angeles, CA
  • United States

Arie Belldegrun Investments (5)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Kronos Bio 13-Jul-2019 Early Stage VC 00000 Biotechnology Startup 0000 0000000000 00
000000 000 23-May-2018 0000 00000 0000 Biotechnology Startup 0000 0000000000 00
000000 000 24-Jul-2016 00000 00000 00.00 Drug Delivery Generating Revenue/Not Profitable 0000 0000000000 00
Kite Pharma 20-Jun-2014 IPO 00000 Biotechnology Profitable 0000 0000000000 00
Cell Design Labs Early Stage VC 00.00 Biotechnology Generating Revenue 0000 0000000000 00
To view this investor’s complete investment and acquisition history, request access »
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Arie Belldegrun’s full profile, request a free trial.

Arie Belldegrun Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
Entera Bio 28-Jun-2018 IPO 000.00 Completed
0000 000000 0000 01-Dec-2017 000000000000000000 00000 Completed
  • 000000 00000000
0000 000000 03-Oct-2017 000000000000000000 0000 Completed
  • 000000 00000000
To view this investor’s complete exits history, request access »

Arie Belldegrun Team (1)

Name Title Deals Funds Boards Office Contact
Arie Belldegrun MD Angel Investor 00 0 0 Los Angeles, CA

Arie Belldegrun Co-Investors (13)

Name With Exits Lead Partner
GV 1 0
Nextech Invest 0 0
Omega Fund 0 0
Polaris Partners 0 0
The Invus Group 0 0
To view this investor’s complete co-investor history, request access »